Richard Law's Stock Ratings

Goldman Sachs Analyst

Richard Law is an analyst at Goldman Sachs. Analyst ratings are quantitative and qualitative analysis of a stock by Wall Street stock rating analysts. Stock ratings consist of expected future growth, current stock valuation and macroeconomic trends. Updated 07/12/2024

Overall Average Return

3.93%

Smart Score

50.2%

Overall Average Return Percentile

45th

Number of Ratings

52
Buy NowGet Alert
06/06/2024VRDNBuy Now
Viridian Therapeutics
$14.6756.78% → $23Initiates → BuyGet Alert
04/02/2024MLYSBuy Now
Mineralys Therapeutics
$14.58105.76% → $30Initiates → BuyGet Alert
04/02/2024OLMABuy Now
Olema Pharmaceuticals
$13.1482.65% → $24Initiates → BuyGet Alert
04/02/2024RCKTBuy Now
Rocket Pharmaceuticals
$22.5572.95% → $39Initiates → NeutralGet Alert
04/02/2024MLTXBuy Now
MoonLake
$46.6832.81% → $62Initiates → NeutralGet Alert
08/11/2023GLUEBuy Now
Monte Rosa Therapeutics
$4.19162.53% → $11ReiteratesNeutral → NeutralGet Alert
08/11/2023VERVBuy Now
Verve Therapeutics
$7.10336.62% → $31ReiteratesNeutral → NeutralGet Alert
08/09/2023OLMABuy Now
Olema Pharmaceuticals
$13.1436.99%$16 → $18MaintainsOutperformGet Alert
08/09/2023BEAMBuy Now
Beam Therapeutics
$25.6283.45%$46 → $47MaintainsNeutralGet Alert
08/08/2023MLYSBuy Now
Mineralys Therapeutics
$14.58153.77%$38 → $37MaintainsOutperformGet Alert
08/08/2023CRSPBuy Now
CRISPR Therapeutics
$57.449.68%$62 → $63MaintainsNeutralGet Alert
08/04/2023KYMRBuy Now
Kymera Therapeutics
$45.01-17.8%$36 → $37MaintainsNeutralGet Alert
06/13/2023NTLABuy Now
Intellia Therapeutics
$26.26189.41% → $76ReiteratesOutperform → OutperformGet Alert
06/05/2023KYMRBuy Now
Kymera Therapeutics
$45.01-20.02% → $36ReiteratesNeutral → NeutralGet Alert
05/16/2023MLYSBuy Now
Mineralys Therapeutics
$14.58160.63% → $38ReiteratesOutperform → OutperformGet Alert
05/12/2023FIXXBuy Now
Homology Medicines
—— → $36ReiteratesNeutral → NeutralGet Alert
05/12/2023GLUEBuy Now
Monte Rosa Therapeutics
$4.19162.53% → $11ReiteratesNeutral → NeutralGet Alert
05/09/2023CRSPBuy Now
CRISPR Therapeutics
$57.447.94%$65 → $62MaintainsNeutralGet Alert
05/08/2023EDITBuy Now
Editas Medicine
$5.70145.61%$15 → $14MaintainsNeutralGet Alert
05/08/2023ARVNBuy Now
Arvinas
$29.97103.54% → $61Reiterates → OutperformGet Alert
05/05/2023KYMRBuy Now
Kymera Therapeutics
$45.01-20.02%$39 → $36MaintainsNeutralGet Alert
03/17/2023GLUEBuy Now
Monte Rosa Therapeutics
$4.19162.53%$12 → $11MaintainsNeutralGet Alert
03/16/2023MLYSBuy Now
Mineralys Therapeutics
$14.58160.63%$40 → $38MaintainsOutperformGet Alert
03/10/2023OLMABuy Now
Olema Pharmaceuticals
$13.14-16.29%$12 → $11MaintainsOutperformGet Alert
03/07/2023MLYSBuy Now
Mineralys Therapeutics
$14.58174.35% → $40Initiates → OutperformGet Alert
02/24/2023NTLABuy Now
Intellia Therapeutics
$26.26189.41%$88 → $76MaintainsOutperformGet Alert
02/24/2023ARVNBuy Now
Arvinas
$29.97103.54%$81 → $61MaintainsOutperformGet Alert
02/24/2023KYMRBuy Now
Kymera Therapeutics
$45.01-13.35%$32 → $39MaintainsNeutralGet Alert
02/23/2023EDITBuy Now
Editas Medicine
$5.70163.16%$13 → $15MaintainsNeutralGet Alert
02/22/2023CRSPBuy Now
CRISPR Therapeutics
$57.4413.16%$78 → $65MaintainsNeutralGet Alert
02/22/2023OLMABuy Now
Olema Pharmaceuticals
$13.14-8.68% → $12Initiates → OutperformGet Alert
12/06/2022NTLABuy Now
Intellia Therapeutics
$26.26235.11%$109 → $88MaintainsOutperformGet Alert
12/06/2022EDITBuy Now
Editas Medicine
$5.70128.07% → $13Assumes → NeutralGet Alert
12/06/2022KYMRBuy Now
Kymera Therapeutics
$45.01-28.9%$47 → $32DowngradeOutperform → NeutralGet Alert
11/08/2022BEAMBuy Now
Beam Therapeutics
$25.62106.87%$65 → $53MaintainsNeutralGet Alert
11/04/2022KYMRBuy Now
Kymera Therapeutics
$45.014.42%$61 → $47MaintainsOutperformGet Alert
11/04/2022NTLABuy Now
Intellia Therapeutics
$26.26315.08%$101 → $109MaintainsOutperformGet Alert
11/02/2022CRSPBuy Now
CRISPR Therapeutics
$57.4435.79%$90 → $78MaintainsNeutralGet Alert
10/06/2022VERVBuy Now
Verve Therapeutics
$7.10576.06% → $48Initiates → NeutralGet Alert
08/16/2022FIXXBuy Now
Homology Medicines
——$55.8 → $57.78MaintainsNeutralGet Alert
08/10/2022KYMRBuy Now
Kymera Therapeutics
$45.0135.53%$60 → $61MaintainsOutperformGet Alert
08/09/2022CRSPBuy Now
CRISPR Therapeutics
$57.4456.69%$74 → $90MaintainsNeutralGet Alert
08/05/2022ARVNBuy Now
Arvinas
$29.97160.26%$98 → $78MaintainsOutperformGet Alert
05/17/2022FIXXBuy Now
Homology Medicines
——$48.6 → $37.8MaintainsNeutralGet Alert
05/06/2022NTLABuy Now
Intellia Therapeutics
$26.26273.19%$100 → $98MaintainsOutperformGet Alert
04/28/2022CRSPBuy Now
CRISPR Therapeutics
$57.4435.79% → $78Initiates → NeutralGet Alert
04/28/2022ARVNBuy Now
Arvinas
$29.97247.01% → $104Initiates → OutperformGet Alert
04/28/2022BEAMBuy Now
Beam Therapeutics
$25.62142% → $62Initiates → NeutralGet Alert
04/28/2022GLUEBuy Now
Monte Rosa Therapeutics
$4.19353.46% → $19Initiates → NeutralGet Alert
04/28/2022KYMRBuy Now
Kymera Therapeutics
$45.0139.97% → $63Initiates → OutperformGet Alert
04/28/2022FIXXBuy Now
Homology Medicines
—— → $48.6Initiates → NeutralGet Alert
04/28/2022NTLABuy Now
Intellia Therapeutics
$26.26280.81% → $100Initiates → OutperformGet Alert

Recent Analyst Stock Rating News

Trump's Family Reacts To Attempted Assassination: 'Toughest Man I've Ever Met'
Following the attempted assassination of former President Donald Trump on Saturday, his family shared heartfelt messages.
Elon Musk's Legal Foes Demand Billions In Fees, Call Tesla CEO's Attempts To Reinstate Pay Plan As 'Clown Show'
Tesla Inc and the plaintiffs who successfully contested CEO Elon Musk's massive compensation package recently clashed in court over a multibillion-dollar attorney fee.
It's Unconstitutional: Hemp Businesses Sue Wyoming Governor Over Law Banning Delta-8 And Similar Substances
The law banning delta-8 cannabis products took effect Monday, and now The Hemp Community of Wyoming is suing the state seeking injunction.
Glencore, Other Experts Say US Permitting System Holding Back Domestic Battery Metals Industry
Experts say slow permitting system hinders U.S. battery materials supply chain. Companies urge for reform to reduce uncertainty and project costs.
Tesla CEO Elon Musk Calls For Legal Reform On Class Action Lawsuits: 'Serving Simply To Enrich Law Firms At The Expense Of The People'
Billionaire entrepreneur Elon Musk on Saturday urged for a change in the law pertaining to class action lawsuits to mandate at least 10% of the class represented to vote in favor of it.
Tesla, Elon Musk Slam Lawyers Demanding $5.2B For Voiding His 2018 Pay Package: 'They Deserve To Repay Tesla Legals Costs And Get Nothing!'
Elon Musk criticized lawyers demanding $5.2B in Tesla stock as legal fees for contesting his 2018 pay package, saying they should repay legal costs.
7 Analysts Assess Viridian Therapeutics: What You Need To Know
What's New In Consumer Tech World Last Week? News That You Should Know (May 19-May 25, 2024)
EU gives final nod to AI Act, South Korea supports semiconductor industry, Taiwan confident in TSMC's protection, China's Tencent and iFlytek cut LLM prices, Microsoft teases "Call of Duty 6," Sony developing PlayStation mobile platform.
Peeling Back The Layers: Exploring SoundThinking Through Analyst Insights
Richard Branson Urges Georgia To Revoke 'Awful Bill' Labeled 'The Russian Law' By Opponents As Mass Protests Hit Former Soviet Republic
Richard Branson, the founder of Virgin Group, has called for the withdrawal of a controversial bill in Georgia, amid widespread protests. The bill, if passed, would require organizations receiving over 20% of their funding from abroad to register as "agents of foreign influence."
The Best Trading Research Platform
For Retail Investors and Professional Trades Alike.
Get Started for Free